Appili closes $177,500 first tranche of placement

Executive Summary

• Appili Therapeutics Inc. has closed the first tranche of its previously announced non-brokered private placement, raising aggregate gross proceeds of $177,500.
• The transaction involved the issuance of 7.1 million units at a price of 2.5 cents per unit, with net proceeds designated for working capital and product development.
• The company plans to close a secondary tranche of the private placement in December 2025.

Key Details

• Gross Proceeds: $177,500.
• Units Issued: 7.1 million units.
• Price Per Unit: 2.5 cents.
• Unit Composition: Each unit consists of one Class A common share and one-half of one common share purchase warrant.
• Warrant Terms (Investors): Each warrant entitles the holder to acquire one common share at an exercise price of five cents per share.
• Warrant Expiration: 36 months from the closing date.
• Shareholder Approval Condition: Warrants are not exercisable until shareholder approval is obtained (excluding votes of warrant holders), to be sought no later than the next annual general meeting. If approval is not received, warrants become non-exercisable.
• Finder’s Fees: Aggregate cash payment of $14,200 paid to finders.
• Broker Warrants Issued: 568,000 broker warrants issued in connection with the closing.
• Broker Warrant Terms: Entitle holder to acquire one common share at a price of not less than 2.834 cents per share.
• Broker Warrant Expiration: 24 months from the closing date.
• Broker Warrant Condition: Subject to same shareholder approval requirements as investor warrants; non-exercisable without approval.
• Use of Proceeds: Primarily for working capital purposes and to finance the development of certain product candidates.
• Future Tranche: A secondary tranche of the private placement is planned for closing in December 2025.
• Hold Period: All securities issued are subject to a statutory hold period of four months and one day from the date of issuance.

Notable Quotes

• None provided in the text.